BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25805811)

  • 1. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
    Dennis M; Russell N; Hills RK; Hemmaway C; Panoskaltsis N; McMullin MF; Kjeldsen L; Dignum H; Thomas IF; Clark RE; Milligan D; Burnett AK
    Blood; 2015 May; 125(19):2923-32. PubMed ID: 25805811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
    Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T; Hawtin R; Craig AR; Ravandi F; Maris MB; Stuart RK; Karp JE
    Haematologica; 2015 Feb; 100(2):231-7. PubMed ID: 25381131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
    Ravandi F; Ritchie EK; Sayar H; Lancet JE; Craig MD; Vey N; Strickland SA; Schiller GJ; Jabbour E; Erba HP; Pigneux A; Horst HA; Recher C; Klimek VM; Cortes J; Roboz GJ; Odenike O; Thomas X; Havelange V; Maertens J; Derigs HG; Heuser M; Damon L; Powell BL; Gaidano G; Carella AM; Wei A; Hogge D; Craig AR; Fox JA; Ward R; Smith JA; Acton G; Mehta C; Stuart RK; Kantarjian HM
    Lancet Oncol; 2015 Sep; 16(9):1025-1036. PubMed ID: 26234174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.
    Burnett AK; Russell N; Hills RK; Panoskaltsis N; Khwaja A; Hemmaway C; Cahalin P; Clark RE; Milligan D
    Leukemia; 2015 Jun; 29(6):1312-9. PubMed ID: 25676423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
    Burnett AK; Hills RK; Hunter AE; Milligan D; Kell WJ; Wheatley K; Yin J; McMullin MF; Dignum H; Bowen D; Russell NH;
    Leukemia; 2013 Jan; 27(1):75-81. PubMed ID: 22964882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia.
    Huang J; Gui C; Zhang L; Che F; Wang C
    Cell Physiol Biochem; 2018; 49(4):1589-1599. PubMed ID: 30223267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
    Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
    J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
    Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Daver N; Kantarjian H; Garcia-Manero G; Jabbour E; Borthakur G; Brandt M; Pierce S; Vaughan K; Ning J; Nogueras González GM; Patel K; Jorgensen J; Pemmaraju N; Kadia T; Konopleva M; Andreeff M; DiNardo C; Cortes J; Ward R; Craig A; Ravandi F
    Haematologica; 2017 Oct; 102(10):1709-1717. PubMed ID: 28729302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Dennis M; Burnett A; Hills R; Thomas I; Ariti C; Severinsen MT; Hemmaway C; Greaves P; Clark RE; Copland M; Russell N;
    Br J Haematol; 2021 Jul; 194(2):298-308. PubMed ID: 33961292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
    Jamieson GC; Fox JA; Poi M; Strickland SA
    Drugs; 2016 Sep; 76(13):1245-1255. PubMed ID: 27484675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
    Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
    Hotinski AK; Lewis ID; Ross DM
    Expert Opin Pharmacother; 2015 Jun; 16(9):1395-402. PubMed ID: 25958926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
    Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
    J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.
    Burnett AK; Hills RK; Hunter A; Milligan D; Kell J; Wheatley K; Yin J; McMullin MF; Cahalin P; Craig J; Bowen D; Russell N
    Leukemia; 2011 Jul; 25(7):1122-7. PubMed ID: 21475252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
    Stuart RK; Cripe LD; Maris MB; Cooper MA; Stone RM; Dakhil SR; Turturro F; Stock W; Mason J; Shami PJ; Strickland SA; Costa LJ; Borthakur G; Michelson GC; Fox JA; Leavitt RD; Ravandi F
    Br J Haematol; 2015 Mar; 168(6):796-805. PubMed ID: 25403830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
    J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
    Lancet JE; Ravandi F; Ricklis RM; Cripe LD; Kantarjian HM; Giles FJ; List AF; Chen T; Allen RS; Fox JA; Michelson GC; Karp JE
    Leukemia; 2011 Dec; 25(12):1808-14. PubMed ID: 21760592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.